Latest blog
New Publication on CMC-001
In the recent edition of Investigative Radiology Dr. Matthias Reif and colleagues at the Charité – Universitätsmedizin in Berlin, Germany have published an article from a phase II with CMC-001 entitled; “Manganese-Based Oral Contrast Agent for Liver Magnetic Resonance Imaging - Evaluation of the Time Course and Dose Response of Liver Signal Intensity Enhancement” (Rief M et al .Invest Radiol 2010; 45).
Based on the results from the study Dr. Reif and colleagues concluded:
“In conclusion, our study demonstrates that CMC-001 administered as sin...
Introduction
CMC Contrast AB
CMC Contrast AB was established in April 2000 with the purpose to develop targeted contrast media for MRI. Ideas and products have been patented, tested and developed in an extensive network of industrial partners, and academic partners and subcontractors. CMC Contrast AB is investor owned.
Read more about CMC Contrast
